Protective Effect of Astragalus Membranaceus and Astragaloside IV in Sepsis-induced Acute Kidney Injury
Overview
Authors
Affiliations
Background: Acute kidney injury (AKI) is the most common target organ damage in sepsis. Sepsis-associated AKI (SA-AKI) may be characterized by damage to the renal tubular epithelium. In this study, the pharmacological mechanisms of Astragalus membranaceus and its active monomer Astragaloside IV (AS-IV) were predicted based on a network pharmacology approach and validated both and using the SA-AKI model.
Method: We constructed an sepsis model using a mouse cecum ligation puncture (CLP) and HK-2 cells were treated with lipopolysaccharide (LPS) to mimic Gram (-) induced sepsis to assess the renal-protective efficacy of Astragalus membranaceus and AS-IV.
Results: The findings demonstrated that Astragalus membranaceus and AS-IV attenuate renal tubular injury in mice with polymicrobial sepsis, including vacuolization, loss of brush border, mitochondrial ultrastructural changes, and increased staining of kidney injury molecule-1 (KIM-1). AS-IV protected human proximal tubular epithelial (HK-2) cells against LPS induced cell viability loss. Both Astragalus membranaceus and AS-IV activated the PI3K/AKT pathway both and , as shown by Western blot and immunohistochemistry analysis.
Conclusion: The findings demonstrate that Astragalus membranaceus and AS-IV protect against sepsis-induced kidney tubular injury by activating the PI3K/AKT pathway.
Chen L, Deng Y, Hu J, Gong X Front Pharmacol. 2025; 16:1539886.
PMID: 40046749 PMC: 11880292. DOI: 10.3389/fphar.2025.1539886.
Lu K, Kuo K, Wu S, Lin C, Lin C, Hou Y Int J Med Sci. 2025; 22(1):227-239.
PMID: 39744164 PMC: 11659832. DOI: 10.7150/ijms.102280.
Role of HSP90 in Type 2 Diabetes Mellitus and Its Association with Liver Diseases.
Nithyasree V, Magdalene P, Praveen Kumar P, Preethi J, Gromiha M Mol Biotechnol. 2024; .
PMID: 39162909 DOI: 10.1007/s12033-024-01251-1.
Hao J, Zhang X, Hu R, Lu X, Wang H, Li Y J Transl Med. 2024; 22(1):555.
PMID: 38858642 PMC: 11163744. DOI: 10.1186/s12967-024-05355-9.
Mechanism of Astragaloside IV in Treatment of Renal Tubulointerstitial Fibrosis.
Wang X, Luan J, Guo Z Chin J Integr Med. 2024; .
PMID: 38850482 DOI: 10.1007/s11655-024-3805-6.